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Abstract
Background: HIV incidence was substantially lower among circumcised versus uncircumcised heterosexual African men in
three clinical trials. Based on those findings, we modeled the potential effect of newborn male circumcision on a U.S. male’s
lifetime risk of HIV, including associated costs and quality-adjusted life-years saved.
Methodology/Principal Findings: Given published estimates of U.S. males’ lifetime HIV risk, we calculated the fraction of
lifetime risk attributable to heterosexual behavior from 2005–2006 HIV surveillance data. We assumed 60% efficacy of
circumcision in reducing heterosexually-acquired HIV over a lifetime, and varied efficacy in sensitivity analyses. We
calculated differences in lifetime HIV risk, expected HIV treatment costs and quality-adjusted life years (QALYs) among
circumcised versus uncircumcised males. The main outcome measure was cost per HIV-related QALY saved. Circumcision
reduced the lifetime HIV risk among all males by 15.7% in the base case analysis, ranging from 7.9% for white males to
20.9% for black males. Newborn circumcision was a cost-saving HIV prevention intervention for all, black and Hispanic
males. The net cost of newborn circumcision per QALY saved was $87,792 for white males. Results were most sensitive to
the discount rate, and circumcision efficacy and cost.
Conclusions/Significance: Newborn circumcision resulted in lower expected HIV-related treatment costs and a slight
increase in QALYs. It reduced the 1.87% lifetime risk of HIV among all males by about 16%. The effect varied substantially by
race and ethnicity. Racial and ethnic groups who could benefit the most from circumcision may have least access to it due
to insurance coverage and state Medicaid policies, and these financial barriers should be addressed. More data on the long-
term protective effect of circumcision on heterosexual males as well as on its efficacy in preventing HIV among MSM would
be useful.
Citation: Sansom SL, Prabhu VS, Hutchinson AB, An Q, Hall HI, et al. (2010) Cost-Effectiveness of Newborn Circumcision in Reducing Lifetime HIV Risk among U.S.
Males. PLoS ONE 5(1): e8723. doi:10.1371/journal.pone.0008723
Editor: Patricia Kissinger, Tulane University, United States of America
Received May 29, 2009; Accepted December 15, 2009; Published January 18, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sos9@cdc.gov
Introduction
Three randomized, controlled clinical trials conducted in South
Africa, Kenya, and Uganda found that medical circumcision in men
reduced participants’ risk of HIV infection [1–3]. In these studies,
menwhohadbeenrandomlyassignedtothecircumcisiongrouphad
a lower (60% in South Africa, 53% in Kenya, and 51% in Uganda)
incidence of HIV infection compared with men assigned to the wait
list group to be circumcised at the end of the study. In a per protocol
analysis, men who had been circumcised had a 76% (South Africa),
60% (Kenya), and 55% (Uganda) reduction in risk of HIV infection
compared to those who were not circumcised. In Kenya, efficacy
increased to 64% when the follow-up period was extended from 24
to 42 months (Bailey RC, Moses S, Parker CB, Agot K, Maclean I,
et al. The protective effect of male circumcision is sustained for at
least 42 months: results from the Kisumu, Kenya trial. XVII
International AIDS Conference. Aug. 3–8, 2008. Mexico City, Mexico.).
Based on the results of these studies, the World Health
Organization (WHO) has recommended that male circumcision
be recognized as an efficacious intervention for HIV prevention in
countries and regions with heterosexual epidemics, high HIV and
low male circumcision prevalence. Circumcision should be
considered as part of a comprehensive HIV prevention package
and not a replacement for known methods of HIV prevention [4].
The WHO noted that the partially-protective effect of male
circumcision for heterosexual men was remarkably consistent
across observational studies as well as across the three randomized,
controlled clinical trials assessed in this paper [5].
In the United States, there are limited observational data on the
protective efficacy of circumcision for heterosexual males; and the
methods used in existing studies differ. A 2008 cross-sectional
study of African-American males attending a sexually transmitted
disease clinic, and with known exposure to HIV, indicated an
adjusted HIV prevalence rate ratio of 0.49 (95% Confidence
Interval [CI]: 0.26–0.93) among circumcised men compared with
uncircumcised men [6]. A 1993 prospective study of men
attending an inner-city sexually transmitted disease clinic, whose
exposure to HIV was calculated based on participants’ reports of
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had an adjusted odds ratio of HIV seroconversion of 3.5. The 95%
confidence interval, however, was 0.8 to 15.8 [7].
Among men who have sex with men (MSM), results from a
meta-analysis of 15 observational studies on male circumcision did
not find a statistically significant association between circumcision
and HIV status [8]. An analysis of Australian MSM with a
preference for the insertive role in anal intercourse found a
significant reduction in HIV incidence among circumcised men
with HIV-infected partners or those whose HIV status was
unknown, compared with uncircumcised men (hazard rate 0.11,
95% CI: 0.03–0.8, p=0.041) [9].
Although mathematical models have demonstrated a potentially
large reduction in HIV incidence among heterosexuals in Africa as
the practice of circumcision increases [10–13], the potential
impact of circumcision is less well-understood in the United States,
where the majority of HIV infection among U.S. males occurs
through sexual contact with other males, and the prevalence of
male circumcision already is high [14,15]. We examine the
potential effectiveness and cost-effectiveness of newborn circum-
cision on reducing a U.S. male’s lifetime risk of HIV by applying
efficacy data from the African trials to the portion of U.S. males’
lifetime HIV risk related to heterosexual contact.
Methods
Institutional review board consideration was not required for
this work because it did not involve the collection or analysis of
primary data. We developed a static Excel-based (Version 2003,
Microsoft Corporation, WA) decision model to compare the
HIV-related costs and quality-adjusted life-years among U.S.
males who are circumcised at birth with those who are not. We
based our analysis on previously published estimates of lifetime
HIV risk for U.S. males[16]. We calculated the expected
difference in lifetime HIV risk among circumcised and
uncircumcised males given the portion of lifetime HIV risk
attributed to heterosexual contact, the prevalence of circumci-
sion in the United States and the observed efficacy of
circumcision on HIV prevention in Africa. Our work is
consistent with reference-case recommendations of the Panel
on Cost-Effectiveness in Health and Medicine for conducting
and reporting cost-effectiveness analyses, including the use of a
societal perspective [17].
Analytic parameters from published sources are in Table 1.
Lifetime HIV risk for U.S. males overall, and by race/ethnicity,
has been estimated at 1.87%, 0.96%, 2.88% and 6.23% among
all, white, Hispanic and black males, respectively[16].
Based on the African adult circumcision trial data, we assumed
the efficacy of circumcision for the prevention of heterosexually
acquired HIV was 60% over a lifetime, compared with
uncircumcised men. In sensitivity analyses, we averaged the lower
and upper bounds from the 95% confidence intervals reported in
the per-protocol analyses from the African trials, 39% and 80%
[1–3]. We assumed in the base case that circumcision conferred no
protection for the MSM transmission category. In a sensitivity
analysis, we assumed as high as a 20% efficacy for that category
[8,9,18–21].
The prevalence of circumcision among U.S. males born from
1940 through 1979 was 79% overall, 88% for white males, 73%
for black males and 42% for Mexican American males [15]. We
Table 1. Key parameters for assessing the cost-effectiveness of newborn circumcision in reducing lifetime HIV risk among U.S.
males.
Variable (reference) Base Range
Lifetime HIV risk among U.S. males[16] (%)
All
Black
Hispanic
White
1.87
6.23
2.88
0.96
95% CI*
1.86–1.89
6.14–6.33
2.78–2.99
0.95–0.98
Lifetime circumcision efficacy (%)
Heterosexually acquired HIV[1–3]
HIV acquired through sex with men{
60
0
95% CI
39–80
0–20
Prevalence of male circumcision[15] (%)
All
Black
Hispanic
White
79
73
42
88
95% CI
77–80
69–77
40–45
87–90
Average age of HIV infection among men (years){ 34 32–36
Remaining life expectancy after HIV infection (years) [23] 32 32
Total life expectancy without HIV infection (years) [24] 77 77
Expected quality-adjusted life-years without HIV infection, discounted to birth 30.81 30.37–30.91
Expected quality-adjusted life-years with HIV infection, depending on year of infection,
discounted to birth [31]
28.66 27.94–28.82
Lifetime cost of HIV discounted to birth ($) [23] 127,298 81,109–165,487
Cost of neonatal circumcision ($) [25,29] 257 216–601
Discount rate (%) 3.0 1.0–5.0
*CI=Confidence Interval.
{Assumption.
{Written communication from R Song, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, August 2008.
doi:10.1371/journal.pone.0008723.t001
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Hispanic males. In sensitivity analyses we used the lower and
upper limits of the 95% confidence interval for circumcision
prevalence among all males and specific to race and ethnicity.
We chose 34 years as the median age of HIV infection among
U.S. males based on 2006 HIV incidence data (written
communication from R Song, Division of HIV/AIDS Preven-
tion, Centers for Disease Control and Prevention, August 2008.
See also [22]). In a sensitivity analysis, we varied the median age
of infection between 30 and 38 years. We assumed a life
expectancy of 32 additional years for males infected with HIV,
and HIV lifetime treatment costs discounted to the time of
infection of $343,129 [23]. We further discounted HIV lifetime
treatment costs at 3% per year from the age of infection to birth
to generate lifetime HIV treatment costs of $127,298. In a
sensitivity analysis, we varied lifetime HIV treatment costs by
25%. We also varied the discount rates for lifetime treatment
costs and quality-adjusted life-years from 0% to 5%. We
a s s u m e dt h a tu n i n f e c t e dm e nh a da na v e r a g el i f ee x p e c t a n c y
of 77 years [24].
The cost of newborn circumcision often includes that for the
physician who performs the procedure and facility-related costs.
We estimated a cost of $257 and a range of $216 to $601, based on
4 published cost estimates plus a review of newborn circumcision
costs in the MarketScan Medicaid database [25–29]. All costs
in the study are adjusted to $US2007, using the medical care
component of the Consumer Price Index.
For all males and by race/ethnicity, we calculated the fraction
of lifetime HIV risk attributable to each transmission category.
The calculation was based on the transmission categories
associated with 2005–2006 new HIV diagnoses of males in the
HIV/AIDS Reporting System in 33 name-based reporting states
(written communication, M. Campsmith, Division of HIV/AIDS
Prevention, Centers for Disease Control and Prevention, July
2008. See also [14,30]). We used the following transmission
categories: MSM, high-risk heterosexuals (HRH), intravenous
drug users (IDU), and others. The HIV/AIDS data also contain
the transmission category MSM/IDU. To simplify our calcula-
tions, we assigned the males in the MSM/IDU HIV transmission
category to either the MSM-only or IDU-only transmission
categories. The assignment of those in the MSM/IDU transmis-
sion category was proportionate to the number of males in the
MSM-only compared with IDU-only category.
The majority of HIV diagnoses (71.4%) for all U.S. males were
associated with sex with men, a route of transmission for which the
efficacy of circumcision appears to be quite limited (Table 2). The
proportion of HIV infections attributable to heterosexual contact
was 15.7% for all males, with considerable variation across race/
ethnicity, ranging from 6.7% for white males to 23.1% for black
males. In sensitivity analyses, we varied the fraction of lifetime risk
attributable to heterosexual contact by 25%.
In our base case analysis, we assumed that the calculated
fraction of lifetime HIV risk attributable to heterosexual activity
reflected a weighted average of the risk among circumcised and
uncircumcised males, and that the lifetime HIV risk of circumcised
males was 60% lower than the lifetime HIV risk of uncircumcised
males. We calculated the lifetime risk of HIV attributable to
heterosexual activity separately for circumcised and uncircumcised
males as follows:
Lh~aLcz 1{a ðÞ Lu and Lc~ 1{g ðÞ Lu
Where:
Lh~ lifetime risk of HIV from heterosexual contact:
a~ proportion of males circumcised:
Lc~ lifetime risk of HIV from heterosexual contact
among circumcised men:
Lu~ lifetime risk of HIV from heterosexual contact
among uncircumcised men:
g~ circumcision efficacy in preventing HIV:
We then summed the fractions of lifetime risk of HIV associated
with each transmission category separately for circumcised and
uncircumcised men to estimate total lifetime HIV risk. In the base
case, we assumed the lifetime risk of HIV associated with sex with
men, intravenous drug users, and other transmission categories
Table 2. U.S. males’ HIV lifetime risk by transmission category.
All males Black Hispanic White
Lifetime HIV Risk (%)
95% CI
1.87
1.86–1.89
6.23
6.14–6.33
2.88
2.78–2.99
0.96
0.95–0.98
Transmission
category
Attributable
%o fH I V
diagnoses
Attributable
portion of
lifetime HIV risk
Attributable %
of HIV
diagnoses
Attributable
portion of
lifetime HIV risk
Attributable %
of HIV
diagnoses
Attributable
portion of
lifetime HIV risk
Attributable %
of HIV
diagnoses
Attributable
portion of
lifetime HIV risk
MSM 71.4 1.33 61.5 3.83 69.2 1.99 84.5 0.81
HRH 15.7 0.29 23.1 1.44 16.2 0.47 6.7 0.06
IDU 12.5 0.23 14.9 .93 14.2 0.41 8.5 0.08
Other 0.4 0.01 ,.01 0.02 0.4 0.01 0.4 ,0.01
doi:10.1371/journal.pone.0008723.t002
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lifetime risk associated with sex with women was different between
the groups of men. We calculated the percentage of difference in
lifetime risk for circumcised versus uncircumcised men and the
number of circumcisions needed to prevent one HIV infection.
We estimated expected lifetime HIV costs among circumcised
and uncircumcised males by multiplying each group’s lifetime risk
of HIV by HIV treatment costs discounted to the time of birth. We
derived expected savings in treatment costs among circumcised
men by subtracting expected lifetime HIV treatment costs among
those men from expected lifetime HIV treatment costs among
uncircumcised men. We estimated net circumcision costs among
circumcised males by subtracting the expected savings in HIV
treatment dollars from the cost of neonatal circumcision. We used
published HIV-related utility estimates to estimate the expected
the number of QALYs saved among circumcised men compared
with uncircumcised males [31].
We performed one-way and multi-way sensitivity analyses to
estimate the effect of various values for each parameter on
incremental cost-effectiveness ratios. We conducted probabilistic
sensitivity analyses, simulating 10,000 iterations for all males and
for black, Hispanic, and white males, to determine the proportion
of incremental cost-effectiveness ratios that fell within thresholds
ranging from cost-saving to $200,000 per QALY saved [32–34].
Results
We estimated that at 60% lifetime efficacy, circumcision would
reduce the lifetime risk of HIV diagnosis for all males by 15.7% in
the base case analysis, and the reduction ranged from 7.9% among
white males to 20.9% for black males (Table 3). The number of
circumcisions needed to prevent one HIV infection was 298 for all
males, and ranged from 65 for black males to 1,231 for white
males. For all males, circumcision increased undiscounted
HIV-related quality-adjusted life expectancy by 19.6 days, and
discounted (at 3%) quality-adjusted life expectancy by 2.6 days.
For all males, circumcision resulted in undiscounted lifetime HIV-
related healthcare savings of $2,070 per male and discounted
lifetime HIV-related healthcare savings of $427. Newborn
circumcision resulted in savings in costs and in quality-adjusted
life-years for all males and for black and Hispanic males. For white
males, newborn circumcision cost $87,792 for each QALY saved,
under base case assumptions.
The variable with the greatest impact on the incremental cost-
effectiveness ratio in one-way sensitivity analyses was the discount
rate, followed by circumcision efficacy in preventing heterosexu-
ally acquired HIV, circumcision cost, and circumcision efficacy in
preventing HIV acquired through sex with men (Table 4). A two-
way sensitivity analysis combining the effect of circumcision
efficacy in preventing heterosexually acquired HIV and the cost of
newborn circumcision indicated the highest incremental cost-
effectiveness ratio for all males is $102,789 when efficacy was
lowest (40%) and the cost of circumcision was highest ($600)
(Table 5).
In a probabilistic sensitivity analysis based on 10,000 iterations,
newborn circumcision was cost-saving for 78.3%, 100%, 88.3%
and .3% of iterations for all, black, Hispanic, and white males,
when no efficacy was assigned to preventing HIV among MSM. It
was cost-saving for 91.0%, 100%, 97.1% and 3.3% of iterations
for the same groups when a 5% efficacy was assumed for MSM
(Table 6). For white males, newborn circumcision was cost-
effective for 67.3% of iterations at a threshold of $150,000 per
QALY saved, and 82.4% of iterations at a threshold of $200,000.
Discussion
A U.S. male has a 1.87% chance of becoming infected with
HIV over his lifetime, and the risk varies substantially by race and
ethnicity, from 0.94% among white males to 6.22% among black
males. Using randomized clinical trial results from Africa, our
analysis shows that newborn circumcision can reduce the lifetime
risk of HIV, and that the protective effect also varies by race/
ethnicity. The reduction is 16% for all males, nearly 21% for black
males, and 8% for white males, given the base case assumption
that the protective effect of circumcision applies only to
heterosexually acquired HIV.
Our analysis indicates that racial and ethnic groups who would
potentially benefit the most from newborn circumcision because
they are at greater risk of HIV transmission through heterosexual
contact, currently, have a lower prevalence of circumcision than
white males. Circumcision prevalence was 73% for black males
and 42% for Mexican American males, compared with 88%
among white males [15]. Based on our estimated number needed
to treat and the 2006 male birth cohorts for blacks (314,670),
Hispanics (530,971), and whites (1,184,120), if the entire racial/
ethnic cohort were circumcised instead of the proportions reported
Table 3. Key cost-effectiveness outcomes for newborn circumcision and the reduction of lifetime HIV risk among U.S. males.
All males Black Hispanic White
Lifetime HIV risk without circumcision (%) 2.14 7.35 3.04 1.03
Lifetime HIV risk with circumcision (%) 1.80 5.82 2.66 0.95
Reduction in lifetime HIV risk (%) 15.7 20.9 12.3 7.9
Number needed to treat to prevent 1 HIV infection 298 65 268 1,231
Expected lifetime HIV treatment costs (discounted) without circumcision ($) 2,718 9,359 3,866 1,313
Expected lifetime HIV treatment costs (discounted0 with circumcision ($) 2,291 7,402 3,391 1,210
Savings in expected lifetime HIV treatment costs ($) 427 1,956 475 103
Net provider costs ($) 2170 21,699 2218 154
Expected QALYs (discounted) with circumcision 30.77 30.68 30.75 30.787
Expected QALYs (discounted) without circumcision 30.76 30.65 30.74 30.785
QALYs saved .007 .033 .008 .002
Net costs/QALY saved ($) Cost saving Cost saving Cost saving 87,792
doi:10.1371/journal.pone.0008723.t003
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cohort of black males, or 6.7% of those expected over their
lifetimes, 1,149 (7.5%) cases would be prevented among Hispanic
males, and 115 (1.0%) of those expected among white males. [35]
Parents,inconsultation with their physician,familymembers and
other health care professionals, decide whether newborn circum-
cision is performed, and these decisions often are made based on
religious or cultural grounds. The decision may be constrained,
however, by health care reimbursement policies. In a 1995 review,
61% of circumcisions were paid for by private insurance, 36% by
Medicaid, and 3% by the parents [36]. In 1999, the American
Academy of Pediatrics revised its policy on newborn circumcision to
state that ‘‘existing scientific evidence demonstrates potential
medical benefits of newborn male circumcision; however, these
data are not sufficient to recommend routine neonatal circumcision
[37].’’ Currently, a number of states have eliminated Medicaid
paymentsforcircumcisionsnotdeemedmedicallynecessary[38].In
states whose Medicaid program covers neonatal circumcision, rates
were reported to be more than twice as high (69.6%) as in states
whose Medicaid program does not pay for male circumcision
(31.2%) [39]. In these latter states, populations most likely to benefit
from newborn circumcision may be least able to obtain it. In 2005,
40% of Hispanic children and 46% of black children were covered
by Medicaid, compared with 19% of white children [40].
Table 4. One-way sensitivity analyses: incremental cost of newborn circumcision per quality-adjusted life-year saved for all U.S.
males and by race/ethnicity.
All males ($) Black males ($) Hispanic males ($) White males ($)
Base case CS CS* CS 87,792
Discount rate=1% CS CS CS CS
Discount rate=5% 52,778 CS 40,740 429,923
Heterosexual efficacy=39% 12,816 CS CS 255,422
Heterosexual efficacy=80% CS CS CS 9,964
Cost of circumcision=$216 CS CS CS 64,351
Cost of circumcision=$601 24,011 CS 15,697 284,474
MSM efficacy=5% CS CS CS 37,402
MSM efficacy=10% CS CS CS 11,018
MSM efficacy=20% CS CS CS CS
Proportion of HIV risk from heterosexual contact: 25% decrease from baseline CS CS CS 136,772
Proportion of HIV risk from heterosexual contact: 25% increase from baseline CS CS CS 58,404
Age of HIV infection=30 years CS CS CS 60,377
Age of HIV infection=38 years CS CS CS 133,730
Discounted lifetime HIV treatment costs=$89,109 CS CS CS 105,536
Discounted lifetime HIV treatment costs=$165,487 CS CS CS 70,048
Circumcision prevalence: lower limit of 95% confidence CS CS CS 89,660
Circumcision prevalence: upper limit of 95% confidence interval CS CS CS 84,057
CS*=cost saving.
doi:10.1371/journal.pone.0008723.t004
Table 5. Two-way sensitivity analysis of efficacy of circumcision related to heterosexually-transmitted HIV and cost of newborn
circumcision on incremental cost per HIV-related quality-adjusted life-year saved for all U.S. males.
Lifetime efficacy of newborn circumcision in preventing heterosexually-acquired HIV among U.S. males
Cost of newborn circumcision 40% 45% 50% 55% 60% 65% 70% 75% 80%
$2 0 0 C S * C SC SC SC S C SC S C S C S
$250 $8,326 CS CS CS CS CS CS CS CS
$300 $21,821 $8 , 6 6 8 C SC SC S C SC S C S C S
$350 $35,316 $19,971 $7,695 CS CS CS CS CS CS
$400 $48,811 $31,274 $17,244 $5,765 CS CS CS CS CS
$450 $62,305 $42,576 $26,793 $13,879 $3,118 CS CS CS CS
$500 $75,800 $53,879 $36,342 $21,993 $10,036 CS CS CS CS
$550 $89,295 $65,181 $45,891 $30,107 $16,955 $5,825 CS CS CS
$600 $102,789 $76,484 $55,439 $38,221 $23,873 $11, 732 $1,325 CS CS
*Cost saving.
doi:10.1371/journal.pone.0008723.t005
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saving in the United States because of the low cost of the
procedure, current lifetime risk of HIV among U.S. males and the
high cost of treating HIV. Previous economic evaluations of
newborn circumcision in the U.S. were published before data on
HIV prevention from the African trials became available. Those
studies typically focused on costs and benefits of circumcision-
associated conditions other than HIV and other STIs. Even when
these benefits were included, the magnitude of the benefit and the
lifetime HIV risk among males were not as well understood. One
study found the expected lifetime cost of circumcision was small,
compared with larger expected benefits [25]. Two of the studies
estimated that both costs and benefits were too small to play an
influential role in the decision whether to perform the procedure
[27,28]. One study found that negative outcomes associated with
circumcision outweighed the benefits [26].
Newborn circumcision for white males in the United States did
not generate cost-saving results. White males already have a high
prevalence of circumcision (88%), a low lifetime risk of HIV
(0.96%) and a low risk of acquiring HIV through heterosexual
contact (6.7%) compared with black and Hispanic males, so
additional circumcisions provide little benefit. The incremental
cost-effectiveness ratio for the base case analysis for white males
was $87,792. A probabilistic sensitivity analysis showed that the
incremental cost-effectiveness ratio fell below $150,000 67.3% of
the time and below $200,000 82% of the time. Historically, a
common cost-effectiveness threshold in the U.S. has been $50,000
per quality-adjusted life-year saved. A more recent analysis of
society’s current willingness to pay for an extra year of life
suggested a range of $183,000 to $264,000 [32]. Others have
suggested a threshold approaching $200,000 or more [33]. The
World Health Organization considers a country-specific threshold
equal to three times the country’s per-capita gross domestic
product [34]. In 2007, the U.S. per capita gross domestic product
was $46,800, or $140,400 when tripled [41].
The choice of discount rate had the biggest effect on the
incremental cost-effectiveness ratio. The impact of discounting is
particularly large in this analysis because the intervention costs are
assumed immediately at birth, but the prevention benefits do not
begin to accrue until more than three decades later. In our base
case, we used the recommended 3% discount rate [17]. Further
guidance on how best to discount benefits that occur in adulthood
following interventions delivered in childhood would be helpful.
Other important factors in the one-way sensitivity analysis were
lifetime efficacy of circumcision in preventing heterosexually-
acquired HIV and the cost of newborn circumcision. However,
even the least favorable inputs generated cost-effective results for
all males. Nonetheless, more research on the long-term efficacy of
circumcision would be useful.
We note that even a modest efficacy in preventing HIV
transmissionamongMSM makestheproceduremore cost-effective.
For white males, an efficacy of 5% improves the cost-effectiveness
ratio from $87,792 in the base case to $37,402. An efficacy of 20%
makes the procedure cost saving for white males. Currently, there
are no data from randomized clinical trials on the benefits of
circumcision inpreventing HIVamongMSM. Thesedata would be
useful in determining the impact of newborn circumcision on HIV
epidemics in developed countries where a significant number of
HIV infections occur through sex among MSM.
Our analysis has two limitations that, if considered, would make
neonatal circumcision more cost-effective. First, our analysis did
not include other health benefits associated with the procedure.
Lack of male circumcision has been associated with increased
incidence of sexually transmitted ulcer disease, infant urinary tract
infections, penile cancer, and cervical cancer in the female
partners of uncircumcised men [42]. One meta-analysis of the
association between male circumcision and risk of genital ulcer
disease concluded that there was a significantly lower risk of
syphilis and chancroids among circumcised men but less effect on
HSV-2 [43]. Further analyses of the randomized, controlled
circumcision trial in Uganda found a 28% decreased cumulative
probability of HSV-2 over 24 months and a lower prevalence of
high-risk HPV genotypes, but no significant difference in the
incidence of syphilis among circumcised trial participants
compared with those who were not circumcised [44]. Subsequent
multivariate analyses of the South African trial data found a 34%
decrease in the incidence of HSV-2 over 21 months among
circumcised compared with uncircumcised males [45].
Second, we did not count secondary HIV transmissions that
would be prevented among partners of circumcised males who
remained uninfected due to circumcision. Models showing the
benefits of circumcision in Africa indicate benefit to female
partners over time as HIV prevalence among men declines
[10–13].
We did not include two factors that could make neonatal
circumcision for HIV prevention less cost-effective. One was the
cost of adverse events associated with newborn circumcision. In
large studies of newborn circumcision in the U.S., complication
rates ranged from 0.2% to 2%, most commonly minor bleeding
and local infection [42]. Another study found a complication rate
of .22% (mostly bleeding) among newborns who were circumcised
before discharge from the hospital, compared with .01% among
those who were not circumcised. The circumcised newborns with
complications had an average hospital stay of 2.81 days compared
with 2.26 days among those circumcised but without complica-
tions [46].
Also, we did not attempt to model potential changes in risky
sexual behaviors among circumcised men. The South African
circumcision trial showed that men in the intervention group had
significantly more sex acts (but not partners) over the course of the
trial, although the protective effect of circumcision remained [1].
The Kenyan and Ugandan trials reported that circumcised men
Table 6. Probability of the cost of newborn circumcision per
HIV-related quality-adjusted life year saved falling within
selected thresholds for all, black, Hispanic and white U.S.
males, with efficacy for the prevention of HIV among MSM
equal to 0% and 5%.
MSM efficacy=0%
Threshold cost-
effectiveness values ($)
All Black Hispanic White
Cost saving 78.3% 100% 88.3% 0.3%
50,000 99.3% 100% 99.9% 13.7%
100,000 100% 100% 100% 41.9%
150,000 100% 100% 100% 67.3%
200,000 100% 100% 100% 82.4%
MSM efficacy=5%
Cost saving 91.0% 100% 97.1% 3.3%
50,000 100% 100% 100% 46.5%
100,000 100% 100% 100% 82.0%
150,000 100% 100% 100% 94.8%
200,000 100% 100% 100% 98.6%
doi:10.1371/journal.pone.0008723.t006
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In Kenya, risk behaviors among circumcised and uncircumcised
men declined over a 12-month period during the trial [47]. As the
benefits of circumcision in preventing heterosexually acquired
HIV become more widely known, circumcised men and their
partners may practice riskier sexual behaviors. On the other hand,
men who have been circumcised since birth may be less likely to
take their circumcision status into account when determining the
level of risk acceptable to them and their partners. Sexual risk
practices should be monitored over time through surveys and safe
sex practices should continue to be encouraged among circum-
cised males and their partners.
We based our analysis on current estimates of lifetime HIV risk,
HiV transmission categories, circumcision prevalence, and costs of
both newborn circumcision and lifetime HIV treatment. These
estimates could change in ways that might make neonatal
circumcision more or less cost-effective over the lifetime of a male
born today.
Although our study accounted for the differences U.S. and
African males in HIV and circumcision prevalence and mode of
HIV transmission, we assumed the protective effect of circumci-
sion observed in the African trials was applicable to U.S. males.
The efficacy of circumcision in all three of the randomized African
trials, which occurred in three different countries, was remarkably
similar. Randomizing participants to immediate or delayed
circumcision is likely to have controlled for other factors that
would have made HIV acquisition more or less likely to occur in
the intervention versus the control groups. It is possible that the
protective effect of circumcision in the African trials was due to the
prevention of HSV-2, which then prevented the acquisition of
HIV, and so the protective effect of circumcision in the United
States would be reduced because of the lower HSV-2 prevalence
among U.S. males. However, investigators from the South African
trial reported that the protective effect of circumcision appeared to
be independent of HSV-2 serostatus. Moreover, the prevalence of
HSV-2 among the South African trial participants was similar to
that among U.S. males [45,48]. Investigators from the Ugandan
trial reported that genital ulcer disease played at most a modest
role in the protection of HIV afforded by circumcision [49]. Thus,
while the absolute incidence of HIV observed among heterosexual
men in the African trials is much larger than that among U.S.
heterosexual males, we assumed the relative 60% decrease in
heterosexual transmission among circumcised compared with
uncircumcised males would hold true regardless of the underlying
prevalence of HIV, circumcision or HSV-2.
This paper evaluates the efficacy of newborn circumcision solely
in the prevention of HIV, and it indicates that the procedure is
cost saving under most scenarios. The greatest risk reduction
occurs for black and Hispanic males. Although our analysis
suggests that newborn circumcision will not have a large impact on
the HIV epidemic in the United States, it could play a role in
reducing the number of new cases of HIV; particularly when used
with other efficacious prevention interventions. Considering
variations in lifetime risk of HIV and circumcision prevalence
among racial and ethnic groups in the U.S., newborn circumcision
may provide one additional tool in reducing longstanding
disparities in HIV incidence [50]. Financial barriers that prevent
parents from having the choice to circumcise their male newborns
should be reduced or eliminated.
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